Briacell Therapeutics Corp. Common Shares (BCTX) Stock Price

BCTXStock
$3.40−71.61%52W
Market Cap$29.58M
P/E—
PEG Ratio—
Div yield—
Beta1.04

BCTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.77%
Price vs S&P 500 (4W)-16.10%
VGM Score39.60

BCTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2025-$12.11$0.04+100.37%(+$12.15)
Q1 2025-$17.60-$16.40+6.82%(+$1.20)
Q4 2024-$19.40-$23.30-20.10%(-$3.90)
Q3 2024-$12.00-$33.00-175.00%(-$21.00)

BCTX Analyst Recommendations

Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.00
4.00
4.00
4.00

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
BCTXBriacell Therapeutics Corp. Common Shares
——D————$3.40
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Briacell Therapeutics Corp. Common Shares

BriaCell Therapeutics is a clinical-stage biotech company developing targeted cell-based immunotherapies for cancer. Lead program Bria-IMT is in end-stage clinical trials for breast cancer, while Bria-OTS offers personalized immunotherapy options for breast and prostate cancer. The company is evaluating combination therapy approaches through clinical collaborations.